Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

17 evidence topics · 26 sources

Summary: injectable administration, treatment delay, and untreated attacks

The approved on-demand C1 inhibitors are given intravenously (plasma-derived C1 inhibitor at 20 IU/kg by intravenous injection; recombinant C1 inhibitor at 50 U/kg as a slow intravenous injection), icatibant is given as a 30 mg subcutaneous injection, and ecallantide as three 10 mg subcutaneous injections; sebetralstat is taken orally. The sponsor states that most on-demand therapies are administered by injection and that this burden causes people to delay or forgo treatment of their attacks. In interviews with 25 US and UK patients and caregivers, participants cited fear of needles, portability, and complexity of administration as reasons for delaying or forgoing injectable on-demand treatment; 80% reported not treating every attack, and some adult and all adolescent patients reported needing assistance with administration.

In a survey of 107 respondents, 57% did not treat all attacks, only 14% treated attacks immediately, and the mean time to treatment was 2.4 h; respondents who waited 1 h or longer cited the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and the treatment being too painful (32.8%), and 32.7% of respondents experienced the return of an attack after initial treatment. Another report of 107 US survey respondents found that 63.6% did not carry on-demand treatment at all times when away from home, 86% reported delaying on-demand treatment, and an average of 20% of attacks were untreated (24% among on-demand-only patients and 15% among prophylaxis patients). In a further US survey, of the 67% of the treated cohort (n = 94) who reported treating early, only 26% administered on-demand treatment in less than 1 hour, 79% reported treatment-related anxiety that correlated with treatment delay, and untreated attacks lasted a mean of 2.3 days. In a survey funded by KalVista Pharmaceuticals, the mean delay from attack onset to on-demand treatment was 2.9 h (SD 2.7), 10% treated within 1 h, 13% sought hospital or emergency services for administration during the last treated attack, 51% required caregiver support, and adolescents and users of intravenous on-demand treatment were more likely to delay treatment because of administration-related barriers. Patients using long-term prophylaxis reported treating a mean of 84.8% of their attacks, compared with 75.6% for patients using on-demand treatment only. In the Icatibant Outcome Survey, 44% of attacks in self-administrators and 22% in patients receiving icatibant from a health care professional were treated within 1 hour of onset, and attack duration was 6.1 hours in patients treated within 1 hour of onset and 16.8 hours in those treated at 1 hour or later.

Summary: adverse reactions, administration by health care professionals, and restrictions of use

Injection site reactions occurred in 97% of patients receiving icatibant in clinical trials. In FDA Adverse Event Reporting System data for the parenteral on-demand therapies, the highest reported rates of administration-site reactions were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year), and access-site complications or malfunctions were reported only for recombinant C1 inhibitor (9.5 per year); these rates are not exposure adjusted. Serious arterial and venous thromboembolic events have been reported with plasma-derived C1 esterase inhibitor products, and plasma-derived C1 inhibitor may carry a risk of transmitting infectious agents. Recombinant C1 inhibitor is contraindicated in patients with allergy to rabbits or rabbit-derived products, and its effectiveness was not established in laryngeal attacks. Anaphylaxis occurred in 10 of 255 participants (4%) treated with ecallantide in clinical studies, and ecallantide is administered only by a health care professional; a guideline suggests it only as a second-line option. Icatibant is indicated for adults 18 years of age and older. Patients who self-administer plasma-derived C1 inhibitor or icatibant for a laryngeal attack are advised to seek medical attention in a health care facility. Plasma products used when HAE-specific treatment is unavailable are available only for in-hospital use, with delays of sometimes up to 24 h in obtaining them.

Users of intravenous C1 inhibitor had higher crude rates of hospitalization (20% vs 6%) and emergency department visits (57% vs 43%) than patients not using an HAE medication requiring intravenous access, and 18 (5.4%) had a central venous access device. Severe laryngeal attacks were not treated in the sebetralstat trial KONFIDENT, and a guideline states that long-term data from extension studies and real-world evidence for sebetralstat are still lacking.

Summary: repeat dosing and rescue medication

Repeat treatment during a single attack is approved for icatibant (up to 3 doses within 24 hours at intervals of at least 6 hours) and for ecallantide and recombinant C1 inhibitor (up to 2 doses within 24 hours); sebetralstat allows a second 600 mg dose at least 3 hours after the first, up to 1,200 mg in any 24-hour period. A guideline states that icatibant more frequently requires a second dose than C1 inhibitor. In Trial 1 of the icatibant label, 3 of 43 participants (7%) treated with icatibant used additional rescue medication, compared with 18 of 45 (40%) with placebo, and in a further analysis in the label, 93% of 987 attacks were treated with a single dose. In the sebetralstat label, 38% of participants in the 600 mg group administered a second dose within 12 hours. Recombinant C1 inhibitor was given as rescue medication to 5 of 44 participants (11%) randomized to it and 13 of 31 (42%) randomized to placebo, and 5 of 170 attacks (3%) in the open-label phase received a second dose. In EDEMA4, 16 of 48 participants (33%) treated with ecallantide and 24 of 48 (50%) given placebo required medical intervention for unresolved symptoms within 24 hours. In the KONFIDENT-S extension, conventional on-demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks treated with sebetralstat.

Summary: attacks and on-demand treatment use during long-term prophylaxis

Guidelines state that long-term prophylaxis does not completely eliminate the risk of attacks and recommend that patients receiving it keep access to on-demand treatment, with at least two doses available. A review of 45 primary studies reported attack-free rates in phase 3 trials of 40% for subcutaneous plasma-derived C1 inhibitor at 16 weeks and 44% for lanadelumab every second week at 6 months, with no difference in attack-free rate for berotralstat versus placebo at 24 weeks; laryngeal attacks accounted for 2% to 7% of attacks, and on-demand therapy was used in 49% to 94% of attacks occurring during prophylaxis. In one claims analysis, on-demand treatment use remained present for over two-thirds of patients after starting prophylaxis, and 55% had refill gaps, discontinued, or switched prophylaxis within a year. Among 196 patients on subcutaneous prophylaxis in another analysis, the mean annualized number of on-demand prescriptions was 3.8 per patient, and in a third, on-demand rescue medication was used during 53% (163/306) of episodes of intravenous C1 inhibitor prophylaxis. In another cohort, patients with at least 12 months on lanadelumab or berotralstat who had an on-demand dispensation were dispensed a mean of 4.3 and 6.5 packages, respectively, in their most recent 12 months, and 22% (15/69) dispensed none. In the KONFIDENT-S extension, 35 participants receiving prophylaxis experienced a mean of 1.7 attacks per month (SD 1.5). A guideline states that only about 50% of patients currently receive long-term prophylaxis, even in high-income countries, and that the higher costs of newer drugs limit their availability.

Untreated attacks, delayed treatment, and attack recurrence: US survey of 107 participants

“A total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most important reasons cited by those who waited 1 h or longer to initiate on-demand treatment were the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and their on-demand treatment being too painful (32.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This work was sponsored by KalVista Pharmaceuticals, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Repeat dosing limits and second-dose frequency with existing on-demand agents